- Home
- BEAM vs FRME Comparison
BEAM vs FRME Comparison
Compare BEAM & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- FRME
- Stock Information
- Founded
- BEAM 2017
- FRME 1893
- Country
- BEAM United States
- FRME United States
- Employees
- BEAM N/A
- FRME N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- FRME Major Banks
- Sector
- BEAM Health Care
- FRME Finance
- Exchange
- BEAM Nasdaq
- FRME Nasdaq
- Market Cap
- BEAM 1.8B
- FRME 2.0B
- IPO Year
- BEAM 2020
- FRME N/A
- Fundamental
- Price
- BEAM $17.00
- FRME $35.53
- Analyst Decision
- BEAM Strong Buy
- FRME Buy
- Analyst Count
- BEAM 11
- FRME 5
- Target Price
- BEAM $50.50
- FRME $46.70
- AVG Volume (30 Days)
- BEAM 3.0M
- FRME 389.4K
- Earning Date
- BEAM 05-06-2025
- FRME 04-24-2025
- Dividend Yield
- BEAM N/A
- FRME 3.94%
- EPS Growth
- BEAM N/A
- FRME N/A
- EPS
- BEAM N/A
- FRME 3.41
- Revenue
- BEAM $63,518,000.00
- FRME $610,994,000.00
- Revenue This Year
- BEAM N/A
- FRME $17.34
- Revenue Next Year
- BEAM $6.32
- FRME $3.94
- P/E Ratio
- BEAM N/A
- FRME $10.42
- Revenue Growth
- BEAM N/A
- FRME N/A
- 52 Week Low
- BEAM $13.53
- FRME $30.55
- 52 Week High
- BEAM $35.25
- FRME $46.13
- Technical
- Relative Strength Index (RSI)
- BEAM 40.71
- FRME 36.69
- Support Level
- BEAM $16.04
- FRME $33.43
- Resistance Level
- BEAM $17.94
- FRME $37.76
- Average True Range (ATR)
- BEAM 1.84
- FRME 1.73
- MACD
- BEAM 0.26
- FRME -0.13
- Stochastic Oscillator
- BEAM 44.24
- FRME 31.58
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.